— Anthem Inc. (NYSE: ANTM) reported Q3 2019 earnings of $4.87 per share, vs. $4.82 expected.
— Revenues grew 15% to $26.4 billion, vs. $25.8 billion expected.
— Medical enrollment totaled 41 million members at quarter-end, up 2.7% from last year.
— Benefit expense ratio was 87.2%, up 240 basis points.
— Days in claims payable was 39.8 days at quarter-end versus 39.1 days last year.
— For full-year 2019, operating revenues are expected to be $103 billion.
— Full-year 2019 GAAP EPS is expected to be greater than $18.45 and adjusted EPS is expected to be greater than $19.40.
— ANTM shares gained 0.10% immediately following the announcement.
Get access to timely and accurate verbatim transcripts that are published within hours of the event.
Most Popular
Biogen (BIIB) stock research summary | Q3 2021
Neurological and neurodegenerative diseases affect a vast segment of the population worldwide and there is a significant demand for treatments for these conditions. Biogen (BIIB) has a strong portfolio of
Teva Pharmaceutical (TEVA) bets on market reopening to regain momentum
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA), a market leader in generic drugs, reported lower revenues for the third quarter of 2021, citing a slowdown in North American sales. Meanwhile, earnings
Goldman Sachs (GS) stock research summary | Q3 2021
Goldman Sachs (GS) exceeded analysts’ expectations, as investment banking revenue surged nearly 90%. Goldman market research report covers key aspects about the firm including company profile, financial highlights and key
